6.52
-0.30 (-4.40%)
| Penutupan Terdahulu | 6.82 |
| Buka | 6.82 |
| Jumlah Dagangan | 1,331,478 |
| Purata Dagangan (3B) | 1,284,129 |
| Modal Pasaran | 422,624,992 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.06 |
| Harga / Jualan (P/S) | 1.54 |
| Harga / Buku (P/B) | 53.71 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -20.40% |
| Margin Operasi (TTM) | -19.00% |
| EPS Cair (TTM) | -0.890 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 15.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2,353.84% |
| Nisbah Semasa (MRQ) | 2.34 |
| Aliran Tunai Operasi (OCF TTM) | -23.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.39 M |
| Pulangan Atas Aset (ROA TTM) | -9.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -949.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Evolus, Inc. Common Stock | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.38 |
|
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.46% |
| % Dimiliki oleh Institusi | 85.15% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 19.00 (Mizuho, 191.41%) | Beli |
| Median | 18.50 (183.74%) | |
| Rendah | 18.00 (BTIG, 176.07%) | Beli |
| Purata | 18.50 (183.74%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 7.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 02 Dec 2025 | 19.00 (191.41%) | Beli | 6.52 |
| BTIG | 08 Sep 2025 | 18.00 (176.07%) | Beli | 7.61 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 Nov 2025 | Pengumuman | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Nov 2025 | Pengumuman | Evolus Reports Third Quarter 2025 Financial Results |
| 28 Oct 2025 | Pengumuman | Evolus to Participate in 2025 Stifel Healthcare Conference |
| 22 Oct 2025 | Pengumuman | Evolus to Report Third Quarter Financial Results on November 5, 2025 |
| 10 Oct 2025 | Pengumuman | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 22 Sep 2025 | Pengumuman | Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch |
| 12 Sep 2025 | Pengumuman | Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 Sep 2025 | Pengumuman | Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |